This is a multicenter, multiple dose, randomized, double-blind, placebo-controlled, forced
titration study. Patients will be randomized to 1 of 4 treatment groups in a 1:1:1:1 ratio.
One-hundred twenty (120) patients are planned to be randomized. Each patient will receive
AR08 (0.5, 1, or 2 mg per day) or matching placebo for seven (7) weeks.